Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 12 54 6 43 15 17 71
Arteriosclerotic Vascular Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2349
MeSH 43 D001161
NCIt 49 C34398
SNOMED-CT 67 28960008
ICD10 32 I70
UMLS 71 C0003850

Summaries for Arteriosclerosis

Disease Ontology : 12 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary : Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and coronary heart disease 1, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and Folate Metabolism. The drugs Pravastatin and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 74 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 35.2 VCAM1 MIR21 ICAM1 HGF ADIPOQ
2 coronary heart disease 1 33.3 VCAM1 SERPINE1 PON1 HS3ST1 HMGCR EDN1
3 lipoprotein quantitative trait locus 33.1 VCAM1 SERPINE1 PON1 MIR21 ICAM1 HMGCR
4 atherosclerosis susceptibility 33.0 VCAM1 SERPINE1 PPARG PON1 MGP ICAM1
5 hypercholesterolemia, familial, 1 32.0 HMGCR COG2 APOB APOA1
6 angina pectoris 31.8 EDN1 APOA1 ADIPOQ
7 peripheral vascular disease 31.7 VCAM1 SERPINE1 HMGCR COG2 CCL2 APOB
8 hypertriglyceridemia, familial 31.7 SERPINE1 APOB APOA1
9 cerebrovascular disease 31.6 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
10 diabetes mellitus 31.6 VCAM1 SPP1 SERPINE1 PPARG PON1 ICAM1
11 ischemia 31.6 PON1 MIR21 ICAM1 HMOX1 EDN1
12 vascular disease 31.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
13 homocysteinemia 31.5 VCAM1 SERPINE1 PON1 ELN CCL2
14 limb ischemia 31.5 SERPINE1 MIR21 ICAM1 HGF EDN1 CCL2
15 lipid metabolism disorder 31.5 SERPINE1 PPARG PON1 MIR21 HMGCR COG2
16 coronary stenosis 31.4 SERPINE1 PON1 MIR21 ICAM1 APOB APOA1
17 fatty liver disease 31.4 PPARG MIR21 APOB ADIPOQ
18 hyperglycemia 31.3 VCAM1 SERPINE1 PPARG APOB ADIPOQ
19 carotid stenosis 31.3 VCAM1 SPP1 ICAM1 ADIPOQ
20 hypothyroidism 31.3 SERPINE1 PON1 COG2 APOB APOA1 ADIPOQ
21 pulmonary hypertension 31.2 SERPINE1 MIR21 HMOX1 EDN1 CCL2
22 familial hypercholesterolemia 31.2 PON1 HMGCR COG2 APOB APOA1 ADIPOQ
23 chronic kidney disease 31.2 VCAM1 SPP1 SERPINE1 PON1 MGP HMOX1
24 aging 31.2 SERPINE1 PPARG EDN1
25 arteries, anomalies of 31.2 VCAM1 SERPINE1 PPARG MIR21 ICAM1 EDN1
26 hyperinsulinism 31.1 SERPINE1 PPARG EDN1 APOB ADIPOQ
27 intermediate coronary syndrome 31.1 VCAM1 COG2 APOB APOA1
28 uremia 31.1 SPP1 PON1 MGP APOA1
29 takayasu arteritis 31.1 VCAM1 ICAM1 EDN1
30 peripheral artery disease 31.1 VCAM1 ICAM1 HMOX1 HGF EDN1 CCL2
31 kidney disease 31.1 VCAM1 SPP1 SERPINE1 PPARG PON1 MGP
32 heart disease 31.1 VCAM1 SERPINE1 PPARG PON1 MIR21 ICAM1
33 body mass index quantitative trait locus 11 31.1 VCAM1 SERPINE1 PPARG PON1 MIR21 ICAM1
34 glomerulonephritis 31.1 VCAM1 SPP1 ICAM1 CCL2
35 hypertension, essential 31.0 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
36 systemic lupus erythematosus 31.0 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
37 carotid artery disease 31.0 PON1 COG2 CCL2 APOB APOA1
38 proteasome-associated autoinflammatory syndrome 1 31.0 VCAM1 PPARG ICAM1 CCL2 ADIPOQ
39 stroke, ischemic 31.0 SERPINE1 PON1 HMGCR COG2 APOB
40 cerebral aneurysms 31.0 ELN CCL2
41 glucose intolerance 31.0 SERPINE1 PPARG CCL2 APOB APOA1 ADIPOQ
42 aortic atherosclerosis 30.9 SPP1 PON1 APOB APOA1 ADIPOQ
43 hyperlipidemia, familial combined, 3 30.9 PON1 COG2 APOB APOA1 ADIPOQ
44 diabetic angiopathy 30.8 VCAM1 EDN1 CCL2
45 retinal vascular disease 30.8 VCAM1 MIR21 ICAM1 EDN1 CCL2
46 non-alcoholic steatohepatitis 30.8 SERPINE1 PPARG MIR21 HGF CCL2 ADIPOQ
47 osteoporosis 30.8 SPP1 SERPINE1 PPARG MIR21 MGP ICAM1
48 non-alcoholic fatty liver disease 30.8 SERPINE1 PPARG MIR21 HMOX1 HMGCR APOB
49 vascular dementia 30.8 PON1 ICAM1 APOA1
50 acute myocardial infarction 30.8 SERPINE1 MIR21 HMGCR EDN1 APOB APOA1

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

MGI Mouse Phenotypes related to Arteriosclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 ADIPOQ APOA1 APOB EDN1 HGF HMOX1
2 growth/size/body region MP:0005378 10.17 ADIPOQ APOB COG2 EDN1 HGF HMGCR
3 homeostasis/metabolism MP:0005376 10.16 ADIPOQ APOA1 APOB COG2 DAB2IP EDN1
4 cellular MP:0005384 10.15 ADIPOQ APOA1 APOB DAB2IP HGF HMOX1
5 liver/biliary system MP:0005370 9.81 ADIPOQ APOA1 APOB HGF HMGCR HMOX1
6 mortality/aging MP:0010768 9.8 ADIPOQ APOB COG2 EDN1 HGF HMGCR
7 muscle MP:0005369 9.23 ADIPOQ APOB EDN1 HMOX1 ICAM1 MGP

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Chlorthalidone Approved Phase 4 77-36-1 2732
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Remifentanil Approved Phase 4 132875-61-7 60815
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Dipyridamole Approved Phase 4 58-32-2 3108
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Ezetimibe Approved Phase 4 163222-33-1 150311
17
Metformin Approved Phase 4 657-24-9 14219 4091
18
Zinc Approved, Investigational Phase 4 7440-66-6 32051
19
Insulin aspart Approved Phase 4 116094-23-6 16132418
20
Insulin detemir Approved Phase 4 169148-63-4 5311023
21
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
22
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
23
Fenofibrate Approved Phase 4 49562-28-9 3339
24
Simvastatin Approved Phase 4 79902-63-9 54454
25
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
26
Propranolol Approved, Investigational Phase 4 525-66-6 4946
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
29
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
30
Sevelamer Approved Phase 4 52757-95-6
31
Calcium acetate Approved, Investigational Phase 4 62-54-4
32
Liraglutide Approved Phase 4 204656-20-2 44147092
33
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
34
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
35
Amlodipine Approved Phase 4 88150-42-9 2162
36
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
37
Testosterone enanthate Approved Phase 4 315-37-7 9416
38
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
39
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
40
Methyltestosterone Approved Phase 4 58-18-4 6010
41
Probucol Approved, Investigational Phase 4 23288-49-5 4912
42
tannic acid Approved Phase 4 1401-55-4
43
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
44
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
47
Mycophenolic acid Approved Phase 4 24280-93-1 446541
48
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
49
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 439)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
3 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
4 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
5 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
6 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
7 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
8 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
9 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
10 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
11 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
12 Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring Unknown status NCT02479789 Phase 4 Lidocaine;Placebo
13 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
14 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
15 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
16 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
17 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
18 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
19 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
20 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
21 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
22 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
23 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
24 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
25 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
26 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
27 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
28 A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease Completed NCT01706510 Phase 4 Ticagrelor;Clopidogrel
29 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
30 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
31 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
32 Pharmacogenomics of Antiplatelet Response - II Completed NCT01894555 Phase 4 Aspirin
33 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
34 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
35 Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA) Completed NCT01325935 Phase 4 Clopidogrel
36 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
37 Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression Completed NCT00204321 Phase 4 sirolimus (drug), mmf (drug)
38 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
39 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
40 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
41 Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids Completed NCT00296153 Phase 4 Omega-3-acid ethyl esters 90
42 Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population Completed NCT02153879 Phase 4 Fenofibrate;Niacin plus laropiprant
43 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo
44 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
45 The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound. Completed NCT01385631 Phase 4 Ezetimibe;Placebo
46 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
47 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
48 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
49 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
50 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

MalaCards organs/tissues related to Arteriosclerosis:

40
Heart, Endothelial, Kidney, Smooth Muscle, Brain, Testes, Bone

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 11710)
# Title Authors PMID Year
1
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 61 54
20097344 2010
2
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 61 54
20150911 2010
3
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 61 54
20078196 2010
4
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 54 61
19066833 2009
5
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 61 54
19132220 2008
6
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 54 61
18464944 2008
7
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 54 61
18670142 2008
8
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 54 61
18332637 2008
9
[Endothelin-1 production and its involvement in cardiovascular diseases]. 54 61
17827914 2007
10
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 54 61
17489075 2007
11
General anesthesia and methylenetetrahydrofolate reductase deficiency. 54 61
18008117 2007
12
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 61 54
17274908 2006
13
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 61 54
16844909 2006
14
Endothelial-mediated regulation of cerebral microcirculation. 54 61
17244945 2006
15
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 54 61
16616959 2006
16
Protective genes in the vessel wall: Modulators of graft survival and function. 61 54
16829794 2006
17
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 54 61
16796604 2006
18
Signaling and functions of angiopoietin-1 in vascular protection. 61 54
16645151 2006
19
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 54 61
16613757 2006
20
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 61 54
16409966 2006
21
Adrenomedullin: a protective factor for blood vessels. 54 61
16141406 2005
22
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 54 61
15882555 2005
23
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 61 54
15744522 2005
24
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 61 54
15578196 2005
25
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 54 61
15550473 2005
26
[Endothelin-1 and arteriosclerosis]. 54 61
15506470 2004
27
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 54 61
15257175 2004
28
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 54 61
15313669 2004
29
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 54 61
15072997 2004
30
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 61 54
15181084 2004
31
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 54 61
15225502 2004
32
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 54 61
14963043 2004
33
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 61 54
14691581 2004
34
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 54 61
12942166 2003
35
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 54 61
14583180 2003
36
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 61 54
14581407 2003
37
[Neurological aspects in antiphospholipid syndrome]. 54 61
15152454 2003
38
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 54 61
12764909 2003
39
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 61 54
12628953 2003
40
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 54 61
15323161 2003
41
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 54 61
12791519 2003
42
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 54 61
12411463 2002
43
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 54 61
12452315 2002
44
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 61 54
12231371 2002
45
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 54 61
12616975 2002
46
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 61 54
12560586 2002
47
A survey of the dietary nutritional composition of centenarians. 54 61
11677774 2001
48
[Effect of lower androgen levels on arteriosclerosis]. 54 61
11769606 2001
49
Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. 61 54
11342471 2001
50
Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis. 61 54
11669408 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HS3ST1 NM_005114.3(HS3ST1):c.-108-6848A>GSNV risk factor 441163 rs16881446 4:11408585-11408585 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis